MorePen Lab - Q3’FY20

• Net Sales Revenue in Q3’FY20 up by 9% at Rs. 226.91 cr Vs Q3’FY19 .
• Net Profit before tax up by 19.7% at Rs. 10.82 cr Vs Rs.9.04 cr in Q3’FY19 .
• Cash Profits up by 2.8% at Rs. 19.36 cr Vs Rs.18.84 cr Y-o-Y.
• Domestic Sales up by 22% to Rs.136.76 cr Vs Rs.111.90 cr .
• Rosuvastatin export jumps 171% and Loratadine export up by 25% in Q3’FY20 Vs Q3’FY19
• Domestic API Sales registered an impressive growth of 76% in Q3’FY20 .
• Atorvastatin Domestic sale spurs 146% in Q3’FY20 Vs Q3’FY19 .
• Nebulisers’ quarterly sales jump up by 89% in Q3’FY20 Vs Q3’FY19.
• Branded Formulations quarterly sales have recorded a handsome growth of 35%.
• Net profit after tax grew by 21.3% at Rs. 10.81 cr Vs Rs. 8.91 cr for Q3’FY19 .